VACC - Vaccitech appoints new Chief Scientific Officer
- Vaccitech ( NASDAQ: VACC ) appoints industry veteran Nadège Pelletier, Ph.D., as Chief Scientific Officer succeeding Tom Evans, who is retiring but will remain involved as a scientific consultant to the company.
-
Most recently, Dr. Pelletier served at Novartis Institutes for Biomedical Research as a discovery leader in a fast-track, multi-indication early clinical program on tolerance induction, and was responsible for maintaining accountability in building solid preclinical packages, biomarker strategies, and translational plans for disease focus and indication expansion.
For further details see:
Vaccitech appoints new Chief Scientific Officer